Meier Michelle, Mortensen Frank V, Madsen Hans Henrik Torp
Department of Surgery, Section for Upper Gastrointestinal and Hepato-pancreatico-biliary Surgery, Aarhus University Hospital, Aarhus, Denmark.
Department of Radiology, Aarhus University Hospital, Aarhus, Denmark.
Acta Radiol Open. 2015 Jul 3;4(7):2058460115579934. doi: 10.1177/2058460115579934. eCollection 2015 Jul.
Malignant ascites is a pathological condition caused by intra- or extra-abdominal disseminated cancer. The object of treatment is palliation. In search of an effective and minimally invasive palliative treatment of malignant ascites placement of a permanent intra peritoneal catheter has been suggested.
To evaluate our experiences with treatment of malignant ascites by implantation of a permanent PleurX catheter.
A retrospective study was conducted, comprising 20 consecutive patients with terminal cancer, who had a permanent PleurX catheter implanted because of malignant ascites in the period from February to November 2014. Using the patients' medical records, we retrieved data on patients and procedures.
The technical success rate was 100%. Catheter patency was 95.2%, one catheter was removed due to dislocation. Ten patients (50.0%) experienced minor adverse events. No procedural difficulties were reported and there was no need for additional treatment of malignant ascites after catheter implantation. Median residual survival after catheter implantation was 27 days.
Implantation of a permanent PleurX catheter is a minimally invasive and effective procedure with only minor adverse events and a high rate of catheter patency in patients with malignant ascites caused by terminal cancer disease.
恶性腹水是由腹内或腹外播散性癌症引起的一种病理状态。治疗目的是缓解症状。为寻找一种有效且微创的恶性腹水姑息治疗方法，有人提出放置永久性腹腔导管。
评估我们使用永久性PleurX导管治疗恶性腹水的经验。
进行了一项回顾性研究，纳入20例晚期癌症连续患者，这些患者在2014年2月至11月期间因恶性腹水植入了永久性PleurX导管。利用患者病历，我们获取了患者和手术相关数据。
技术成功率为100%。导管通畅率为95.2%，一根导管因移位被拔除。10例患者（50.0%）出现轻微不良事件。未报告手术困难，导管植入后无需对恶性腹水进行额外治疗。导管植入后的中位残余生存期为27天。
对于由晚期癌症疾病引起恶性腹水的患者，植入永久性PleurX导管是一种微创且有效的手术，不良事件轻微，导管通畅率高。
